Authors
Chunyang Fan, Yongkang Deng, Jianbing Zhao, Xingzhi Liu, Yao Zhang, Jiechao Xia, Dechun Geng, Xiexing Wu, Haiqing Mao
Published in
Acta biomaterialia. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
Intervertebral disc degeneration (IVDD) is the main cause of low back pain (LBP), current treatment methods are limited due to poor lesion targeting. To address this issue, we designed a multifunctional biomimetic nanoparticle, CeNPs@M1-TPP, which integrates antioxidant, anti-inflammatory, and mitochondria-targeting capabilities into a single platform for synergistic IVDD therapy. The nanoparticle consists of a cerium oxide nanoparticles (CeNPs) core with intrinsic antioxidant activity, enveloped by an M1 macrophage membrane rich in inflammatory cytokine receptors (e.g., TNF-αR, IL-1βR) to enable homotypic targeting (targeting of cells with similar membrane proteins), and further conjugated with the mitochondria-targeting ligand triphenylphosphonium (TPP). The M1 membrane camouflage exerts a dual role: membrane-retained chemokine/adhesion-related proteins facilitate inflammatory tropism and local enrichment in degenerative discs, whereas cytokine receptors subsequently act as decoy receptors to sequester excessive pro-inflammatory cytokines. In vitro studies demonstrate that CeNPs@M1-TPP exhibits inflammation-oriented cellular association and uptake by inflammation-related cells, rather than anatomical localization to inflammatory lesions, and effectively reduces intracellular ROS. This intervention helps restore mitochondrial membrane potential (ΔΨₘ) and ATP synthesis in nucleus pulposus cells (NPCs), while also mitigating degradation of the extracellular matrix (ECM). Additionally, by reducing cytokine-driven inflammatory signaling, the treatment promotes macrophage repolarization, shifting them from a pro-inflammatory M1 state toward a reparative M2 phenotype. After local intradiscal administration, CeNPs@M1-TPP is expected to act mainly through in situ retention within the degenerative disc, interaction with the local inflammatory microenvironment, and mitochondrial targeting in NPCs. Subsequently, in a rat IVDD model, intradiscal injection of CeNPs@M1-TPP significantly improves disc height, MRI T2 signal intensity, and histological scores. Mechanistically, it upregulates the anabolic marker aggrecan while downregulating the catabolic enzyme MMP13 and inflammatory markers (CD86, IL-1β). In conclusion, CeNPs@M1-TPP effectively alleviates IVDD progression through in vitro inflammation-oriented cellular interaction, oxidative stress mitigation, preservation of mitochondrial function, and reprogramming of the immune microenvironment after local intradiscal administration. Bionic nanoplatforms show great potential in treating IVDD. STATEMENT OF SIGNIFICANCE: Intervertebral disc degeneration is driven by oxidative stress, mitochondrial dysfunction, and chronic inflammation. We developed a multifunctional biomimetic CeNPs@M1‑TPP nanoparticle that combines antioxidant ceria nanozyme, M1 macrophage membrane homotypic targeting, and mitochondrial‑targeting TPP. It efficiently scavenges ROS, restores nucleus pulposus cell mitochondrial function, repolarizes macrophages toward anti‑inflammatory M2 phenotype, and ameliorates extracellular matrix degradation. In a rat IVDD model, CeNPs@M1‑TPP significantly alleviates disc degeneration. This integrated strategy provides a promising cascade‑targeted nanotherapeutic for IVDD by breaking the oxidative‑inflammatory cycle.
PMID:
43034030
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0